Evidence map›Paper›PMID 40789799›Full record

ArticleThe AAPS journal2025

A Microemulsion for Oral Delivery of Nintedanib - QbD-Enabled Formulation Development, In-Vitro Characterization & In-Vivo Pharmacokinetic Assessment.

Dnyandev Gadhave, Mural Quadros, Mimansa Goyal, Akanksha R Ugale, Vivek Gupta

Abstract read
PubMed Publisher
In one paragraph

Article in The AAPS journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dnyandev GadhaveDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, 8000 Utopia Parkway, Queens, New York, 11439, USA.
Mural QuadrosDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, 8000 Utopia Parkway, Queens, New York, 11439, USA.
Mimansa GoyalDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, 8000 Utopia Parkway, Queens, New York, 11439, USA.
Akanksha R UgaleDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, 8000 Utopia Parkway, Queens, New York, 11439, USA.
Vivek GuptaDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, 8000 Utopia Parkway, Queens, New York, 11439, USA. guptav@stjohns.edu.ORCID 0000-0002-3618-8178

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nintedanib (Nint) is a potent tyrosine kinase inhibitor recently approved by the US FDA to treat idiopathic pulmonary fibrosis (IPF). Delivery of Nint through available approaches is highly challenging because of its poor solubility and rapid metabolic degradation via hydrolytic ester cleavage, thereby reflecting poor oral bioavailability (< 5%). Hence, the current study was focused on formulating a Nint-loaded microemulsion (Nint-ME) and investigating its therapeutic potential in experimental animals to overcome the constraints of available therapies. Nint-ME was prepared via low-energy O/W emulsification aqueous titration techniques and optimized using QbD approach. Optimized ME subjected to screen for globule size, polydispersity index, encapsulation efficiency, transmittance, surface charge, and viscosity and were found to be 23.8 ± 1.4 nm, 0.18 ± 0.03, 99.8 ± 2.4%, 99.4 ± 0.1%, -0.7 ± 0.01 mV, and 1.5 ± 0.3 cP, respectively. Additionally, 94.5 ± 3.1% Nint was released from Nint-ME through the dialysis cassette within 72 h, demonstrating first-order kinetics with R

Indexed as

IndolesProtein Kinase InhibitorsAdministration, OralAnimalsBiological AvailabilityCaco-2 CellsChemistry, PharmaceuticalDrug CompoundingDrug Delivery SystemsDrug LiberationEmulsionsHumansMaleParticle SizeRatsRats, Sprague-DawleyEmulsionsIndolesnintedanibProtein Kinase Inhibitorscaco-2effluxidiopathic pulmonary fibrosismicroemulsionnintedanibpharmacokineticstransepithelial electrical resistance

Identifiers

PMID40789799

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.